Biologics and Biosimilars Market Report

Europe Biologics and Biosimilars Market Size, Status and Forecast 2014-2026

  • POSTDATE：May 26, 2020
  • PAGES：176
  • REPORT CODE：GMM531803
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Biologics and Biosimilars market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 1.9% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Biologics and Biosimilars Market Segmentations:

    By Player:

    • Eli Lilly

    • Pfizer

    • Amgen

    • Merck

    • United Laboratories

    • Innovent

    • Novo Nordisk

    • Ganlee

    • Dong Bao

    • Roche

    • AbbVie

    • Novartis

    • Biotech

    • Sanofi-Aventis

    • CP Guojian

    • 3sbio

    • Johnson & Johnson

    • Changchun High Tech

    • Gelgen

    By Type:

    • Antibody

    • Hormone

    • Growth Factors

    • Others

    By End-User:

    • Tumor

    • Diabetes

    • Cardiovascular

    • Hemophilia

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Biologics and Biosimilars Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Biologics and Biosimilars Market Size and Growth Rate of Antibody from 2014 to 2026

    • 1.3.2 Europe Biologics and Biosimilars Market Size and Growth Rate of Hormone from 2014 to 2026

    • 1.3.3 Europe Biologics and Biosimilars Market Size and Growth Rate of Growth Factors from 2014 to 2026

    • 1.3.4 Europe Biologics and Biosimilars Market Size and Growth Rate of Others from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Biologics and Biosimilars Market Size and Growth Rate of Tumor from 2014 to 2026

    • 1.4.2 Europe Biologics and Biosimilars Market Size and Growth Rate of Diabetes from 2014 to 2026

    • 1.4.3 Europe Biologics and Biosimilars Market Size and Growth Rate of Cardiovascular from 2014 to 2026

    • 1.4.4 Europe Biologics and Biosimilars Market Size and Growth Rate of Hemophilia from 2014 to 2026

    • 1.4.5 Europe Biologics and Biosimilars Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Biologics and Biosimilars Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Biologics and Biosimilars by Major Types

      • 3.4.1 Market Size and Growth Rate of Antibody

      • 3.4.2 Market Size and Growth Rate of Hormone

      • 3.4.3 Market Size and Growth Rate of Growth Factors

      • 3.4.4 Market Size and Growth Rate of Others

    4 Segmentation of Biologics and Biosimilars Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Biologics and Biosimilars by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Tumor for Construction

      • 4.4.2 Market Size and Growth Rate of Diabetes for Construction

      • 4.4.3 Market Size and Growth Rate of Cardiovascular for Construction

      • 4.4.4 Market Size and Growth Rate of Hemophilia for Construction

      • 4.4.5 Market Size and Growth Rate of Others for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe Biologics and Biosimilars Production Analysis by Top Regions

    • 5.2 Europe Biologics and Biosimilars Consumption Analysis by Top Regions

    • 5.3 Europe Biologics and Biosimilars Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.3 France Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    6 Product Circulation of Biologics and Biosimilars Market among Top Countries

    • 6.1 Top 5 Export Countries in Biologics and Biosimilars Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Biologics and Biosimilars Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Biologics and Biosimilars Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Biologics and Biosimilars Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Biologics and Biosimilars Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Biologics and Biosimilars Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Biologics and Biosimilars Landscape Analysis

    • 7.1 Germany Biologics and Biosimilars Landscape Analysis by Major Types

    • 7.2 Germany Biologics and Biosimilars Landscape Analysis by Major End-Users

    8. UK Biologics and Biosimilars Landscape Analysis

    • 8.1 UK Biologics and Biosimilars Landscape Analysis by Major Types

    • 8.2 UK Biologics and Biosimilars Landscape Analysis by Major End-Users

    9. France Biologics and Biosimilars Landscape Analysis

    • 9.1 France Biologics and Biosimilars Landscape Analysis by Major Types

    • 9.2 France Biologics and Biosimilars Landscape Analysis by Major End-Users

    10. Italy Biologics and Biosimilars Landscape Analysis

    • 10.1 Italy Biologics and Biosimilars Landscape Analysis by Major Types

    • 10.2 Italy Biologics and Biosimilars Landscape Analysis by Major End-Users

    11. Spain Biologics and Biosimilars Landscape Analysis

    • 11.1 Spain Biologics and Biosimilars Landscape Analysis by Major Types

    • 11.2 Spain Biologics and Biosimilars Landscape Analysis by Major End-Users

    12. Poland Biologics and Biosimilars Landscape Analysis

    • 12.1 Poland Biologics and Biosimilars Landscape Analysis by Major Types

    • 12.2 Poland Biologics and Biosimilars Landscape Analysis by Major End-Users

    13. Russia Biologics and Biosimilars Landscape Analysis

    • 13.1 Russia Biologics and Biosimilars Landscape Analysis by Major Types

    • 13.2 Russia Biologics and Biosimilars Landscape Analysis by Major End-Users

    14. Switzerland Biologics and Biosimilars Landscape Analysis

    • 14.1 Switzerland Biologics and Biosimilars Landscape Analysis by Major Types

    • 14.2 Switzerland Biologics and Biosimilars Landscape Analysis by Major End-Users

    15. Turkey Biologics and Biosimilars Landscape Analysis

    • 15.1 Turkey Biologics and Biosimilars Landscape Analysis by Major Types

    • 15.2 Turkey Biologics and Biosimilars Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Landscape Analysis by Top Countries

      • 16.3.1 Denmark Biologics and Biosimilars Market Volume and Growth Rate

      • 16.3.2 Finland Biologics and Biosimilars Market Volume and Growth Rate

      • 16.3.3 Norway Biologics and Biosimilars Market Volume and Growth Rate

      • 16.3.4 Sweden Biologics and Biosimilars Market Volume and Growth Rate

      • 16.3.6 Iceland Biologics and Biosimilars Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Landscape Analysis by Top Countries

      • 17.3.1 Belgium Biologics and Biosimilars Market Volume and Growth Rate

      • 17.3.2 Netherlands Biologics and Biosimilars Market Volume and Growth Rate

      • 17.3.3 Luxembourg Biologics and Biosimilars Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Landscape Analysis by Top Countries

      • 18.3.1 Estonia Biologics and Biosimilars Market Volume and Growth Rate

      • 18.3.2 Latvia Biologics and Biosimilars Market Volume and Growth Rate

      • 18.3.3 Lithuania Biologics and Biosimilars Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Eli Lilly

      • 19.1.1 Eli Lilly Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Pfizer

      • 19.2.1 Pfizer Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Amgen

      • 19.3.1 Amgen Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Merck

      • 19.4.1 Merck Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 United Laboratories

      • 19.5.1 United Laboratories Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Innovent

      • 19.6.1 Innovent Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Novo Nordisk

      • 19.7.1 Novo Nordisk Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Ganlee

      • 19.8.1 Ganlee Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Dong Bao

      • 19.9.1 Dong Bao Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Roche

      • 19.10.1 Roche Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 AbbVie

      • 19.11.1 AbbVie Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Novartis

      • 19.12.1 Novartis Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Biotech

      • 19.13.1 Biotech Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Sanofi-Aventis

      • 19.14.1 Sanofi-Aventis Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 CP Guojian

      • 19.15.1 CP Guojian Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 3sbio

      • 19.16.1 3sbio Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Johnson & Johnson

      • 19.17.1 Johnson & Johnson Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 Changchun High Tech

      • 19.18.1 Changchun High Tech Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    • 19.19 Gelgen

      • 19.19.1 Gelgen Company Profile and Development Status

      • 19.19.2 Market Performance

      • 19.19.3 Product and Service Introduction

    The List of Tables and Figures (Totals 88 Figures and 134 Tables)

    • Figure Product Picture

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Antibody Market, 2015 - 2026 (USD Million)

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Hormone Market, 2015 - 2026 (USD Million)

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Growth Factors Market, 2015 - 2026 (USD Million)

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Others Market, 2015 - 2026 (USD Million)

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Tumor from 2014 to 2026

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Diabetes from 2014 to 2026

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Cardiovascular from 2014 to 2026

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Hemophilia from 2014 to 2026

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure UK Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure France Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Biologics and Biosimilars Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Biologics and Biosimilars

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Biologics and Biosimilars by Different Types from 2014 to 2026

    • Table Consumption Share of Biologics and Biosimilars by Different Types from 2014 to 2026

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Antibody Market, 2015 - 2026 (USD Million)

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Hormone Market, 2015 - 2026 (USD Million)

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Growth Factors Market, 2015 - 2026 (USD Million)

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Others Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Biologics and Biosimilars by Different End-Users from 2014 to 2026

    • Table Consumption Share of Biologics and Biosimilars by Different End-Users from 2014 to 2026

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Tumor from 2014 to 2026

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Diabetes from 2014 to 2026

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Cardiovascular from 2014 to 2026

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Hemophilia from 2014 to 2026

    • Figure Biologics and Biosimilars Market Size and Growth Rate of Others from 2014 to 2026

    • Table Europe Biologics and Biosimilars Production by Major Regions

    • Table Europe Biologics and Biosimilars Production Share by Major Regions

    • Figure Europe Biologics and Biosimilars Production Share by Major Countries and Regions in 2014

    • Table Europe Biologics and Biosimilars Consumption by Major Regions

    • Table Europe Biologics and Biosimilars Consumption Share by Major Regions

    • Table Germany Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table UK Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table France Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Italy Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Spain Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Poland Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Russia Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Switzerland Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Turkey Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Biologics and Biosimilars Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Biologics and Biosimilars Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Biologics and Biosimilars Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Biologics and Biosimilars Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Germany Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Germany Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Germany Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table UK Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table UK Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table UK Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table UK Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table France Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table France Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table France Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table France Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Italy Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Italy Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Italy Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Italy Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Spain Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Spain Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Spain Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Spain Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Poland Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Poland Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Poland Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Poland Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Russia Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Russia Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Russia Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Russia Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Switzerland Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Switzerland Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Switzerland Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Turkey Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Turkey Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Turkey Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Eli Lilly Profiles

    • Table Eli Lilly Production, Value, Price, Gross Margin 2014-2019

    • Table Eli Lilly Product benchmarking

    • Table Eli Lilly Strategic initiatives

    • Table Eli Lilly SWOT analysis

    • Table Pfizer Profiles

    • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

    • Table Pfizer Product benchmarking

    • Table Pfizer Strategic initiatives

    • Table Pfizer SWOT analysis

    • Table Amgen Profiles

    • Table Amgen Production, Value, Price, Gross Margin 2014-2019

    • Table Amgen Product benchmarking

    • Table Amgen Strategic initiatives

    • Table Amgen SWOT analysis

    • Table Merck Profiles

    • Table Merck Production, Value, Price, Gross Margin 2014-2019

    • Table Merck Product benchmarking

    • Table Merck Strategic initiatives

    • Table Merck SWOT analysis

    • Table United Laboratories Profiles

    • Table United Laboratories Production, Value, Price, Gross Margin 2014-2019

    • Table United Laboratories Product benchmarking

    • Table United Laboratories Strategic initiatives

    • Table United Laboratories SWOT analysis

    • Table Innovent Profiles

    • Table Innovent Production, Value, Price, Gross Margin 2014-2019

    • Table Innovent Product benchmarking

    • Table Innovent Strategic initiatives

    • Table Innovent SWOT analysis

    • Table Novo Nordisk Profiles

    • Table Novo Nordisk Production, Value, Price, Gross Margin 2014-2019

    • Table Novo Nordisk Product benchmarking

    • Table Novo Nordisk Strategic initiatives

    • Table Novo Nordisk SWOT analysis

    • Table Ganlee Profiles

    • Table Ganlee Production, Value, Price, Gross Margin 2014-2019

    • Table Ganlee Product benchmarking

    • Table Ganlee Strategic initiatives

    • Table Ganlee SWOT analysis

    • Table Dong Bao Profiles

    • Table Dong Bao Production, Value, Price, Gross Margin 2014-2019

    • Table Dong Bao Product benchmarking

    • Table Dong Bao Strategic initiatives

    • Table Dong Bao SWOT analysis

    • Table Roche Profiles

    • Table Roche Production, Value, Price, Gross Margin 2014-2019

    • Table Roche Product benchmarking

    • Table Roche Strategic initiatives

    • Table Roche SWOT analysis

    • Table AbbVie Profiles

    • Table AbbVie Production, Value, Price, Gross Margin 2014-2019

    • Table AbbVie Product benchmarking

    • Table AbbVie Strategic initiatives

    • Table AbbVie SWOT analysis

    • Table Novartis Profiles

    • Table Novartis Production, Value, Price, Gross Margin 2014-2019

    • Table Novartis Product benchmarking

    • Table Novartis Strategic initiatives

    • Table Novartis SWOT analysis

    • Table Biotech Profiles

    • Table Biotech Production, Value, Price, Gross Margin 2014-2019

    • Table Biotech Product benchmarking

    • Table Biotech Strategic initiatives

    • Table Biotech SWOT analysis

    • Table Sanofi-Aventis Profiles

    • Table Sanofi-Aventis Production, Value, Price, Gross Margin 2014-2019

    • Table Sanofi-Aventis Product benchmarking

    • Table Sanofi-Aventis Strategic initiatives

    • Table Sanofi-Aventis SWOT analysis

    • Table CP Guojian Profiles

    • Table CP Guojian Production, Value, Price, Gross Margin 2014-2019

    • Table CP Guojian Product benchmarking

    • Table CP Guojian Strategic initiatives

    • Table CP Guojian SWOT analysis

    • Table 3sbio Profiles

    • Table 3sbio Production, Value, Price, Gross Margin 2014-2019

    • Table 3sbio Product benchmarking

    • Table 3sbio Strategic initiatives

    • Table 3sbio SWOT analysis

    • Table Johnson & Johnson Profiles

    • Table Johnson & Johnson Production, Value, Price, Gross Margin 2014-2019

    • Table Johnson & Johnson Product benchmarking

    • Table Johnson & Johnson Strategic initiatives

    • Table Johnson & Johnson SWOT analysis

    • Table Changchun High Tech Profiles

    • Table Changchun High Tech Production, Value, Price, Gross Margin 2014-2019

    • Table Changchun High Tech Product benchmarking

    • Table Changchun High Tech Strategic initiatives

    • Table Changchun High Tech SWOT analysis

    • Table Gelgen Profiles

    • Table Gelgen Production, Value, Price, Gross Margin 2014-2019

    • Table Gelgen Product benchmarking

    • Table Gelgen Strategic initiatives

    • Table Gelgen SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US